ANGLE's full potential yet to be recognised by the market, says research house
Portfolio Pulse from
ANGLE PLC, a cancer diagnostics firm, is currently undervalued according to Trinity Delta's research. The firm's shares are trading at 11.45p, but the research suggests a valuation of 48p per share, indicating significant potential for growth.
January 24, 2025 | 9:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ANGLE PLC's shares are currently undervalued at 11.45p, with Trinity Delta valuing them at 48p, suggesting potential for significant price appreciation.
Trinity Delta's research suggests ANGLE PLC is significantly undervalued, with a potential share price four times its current value. This indicates a strong potential for price appreciation, making it an attractive investment opportunity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90